Document is current
Any future updates will be listed below
-
Authors
Cullot, Grégoire https://orcid.org/0000-0003-3925-705X
Aird, Eric J. https://orcid.org/0000-0002-4873-042X
Schlapansky, Moritz F. https://orcid.org/0000-0001-6072-7840
Yeh, Charles D. https://orcid.org/0000-0002-2707-6035
van de Venn, Lilly https://orcid.org/0000-0003-0158-1225
Vykhlyantseva, Iryna
Kreutzer, Susanne
Mailänder, Dominic
Lewków, Bohdan
Klermund, Julia https://orcid.org/0000-0001-6069-8189
Montellese, Christian https://orcid.org/0009-0009-4261-088X
Biserni, Martina
Aeschimann, Florian https://orcid.org/0000-0001-5213-034X
Vonarburg, Cédric
Gehart, Helmuth https://orcid.org/0000-0002-9165-5824
Cathomen, Toni https://orcid.org/0000-0002-7757-4630
Corn, Jacob E. https://orcid.org/0000-0002-7798-5309
-
Funding
Funding for this research was provided by:
EC | Horizon 2020 Framework Programme (855741-DDREAMM-ERC-2019-SyG)
Deutsche Forschungsgemeinschaft (DFG CA 311/4-1)
- License Information
-
More Information
Article History
Received: 30 April 2024
Accepted: 24 October 2024
First Online: 27 November 2024
Competing interests
: J.E.C. is a co-founder and scientific advisory board (SAB) member of Spotlight Therapeutics and Serac Biosciences and an SAB member of Mission Therapeutics, Relation Therapeutics, Hornet Bio, Kano Therapeutics and the Joint AstraZeneca–CRUK Functional Genomics Centre. The laboratory of J.E.C. has funded collaborations with Allogene, Cimeio, CSL Behring and Serac. None of these collaborations is related to this paper. T.C. is an advisor to Cimeio Therapeutics, Excision BioTherapeutics, GenCC and Novo Nordisk. T.C. has sponsored research collaborations with Cellectis. T.C. holds a patent on CAST-seq (US11319580B2). F.A., C.M., M.B. and C.V. are employees of CSL Behring AG. The other authors declare no competing interests.
